EMA Grants PRIME Status to Brensocatib for Treating Non-CF Bronchiectasis
News
The European Medicines Agency (EMA) has given the designation of priority medicines, or PRIME, to Insmed’s brensocatib for the treatment of non-cystic fibrosis bronchiectasis (NCFBE). A PRIME designation is given ... Read more